Articles

Results from two studies demonstrate improved glycemic control, reduction in nighttime- and exercise-induced hypoglycemia with the use of hybrid closed-loop systems.

Why Google, Apple, and Amazon entering the diabetes market is the real big story from ADA.

Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.

Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.

New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.

Recent studies focus on increase in hunger, conclude diet drinks possibly cause an increase in blood sugars.

One long-acting insulin may be better at controlling glycemic variations.

In addition to psychosocial risk factors, disease related factors may also be contributing to bulimic symptoms.

Placing newborns in prospective studies to conduct genetic screenings with follow up may reduce the risk of DKA at diagnosis of type 1.

After 30 years of follow-up studies, DCCT/EDIC study gives findings regarding risk of severe hypoglycemia.